Enliven Therapeutics Inc Stock Price, News & Analysis

Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional $30 million in common stock. The offering is being managed by joint book-runners Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho, with LifeSci Capital as lead manager. The offering will be made through a Registration Statement on Form S-3 and is subject to market conditions and regulatory approval.

Enliven Therapeutics (NASDAQ: ELVN) reported positive Phase 1 data for ELVN-001 in chronic myeloid leukemia (CML) at EHA 2025. The trial showed a 47% cumulative MMR rate by 24 weeks, with 32% achieving and 100% maintaining MMR. Among 90 enrolled patients with median treatment of 29 weeks, 67% received three or more prior TKIs. ELVN-001 demonstrated favorable safety with only 3.4% dose reductions and 4.6% discontinuations due to adverse events. The drug showed promising efficacy in heavily pretreated patients, including those resistant to prior therapies, with MMR rates comparing favorably to historical data. The pharmacokinetic profile supports once-daily dosing, and no maximum tolerated dose was reached. Enliven plans to initiate a head-to-head Phase 3 pivotal trial in 2026.

Enliven Therapeutics (NASDAQ: ELVN), a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, has announced its participation in three major upcoming investor conferences in May and June 2025:

• TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 1:00 p.m. ET
• Jefferies Global Healthcare Conference on June 4, 2025, at 4:20 p.m. ET
• Goldman Sachs Annual Global Healthcare Conference on June 10, 2025, at 4:00 p.m. ET

All presentations will be in fireside chat format and will be webcast live through the company's investor relations website, with recordings available for 90 days after each event.

Enliven Therapeutics (NASDAQ: ELVN) reported Q1 2025 financial results and provided updates on its clinical programs. The company's lead drug ELVN-001, a BCR::ABL kinase inhibitor for chronic myeloid leukemia (CML), showed promising results in the Phase 1 ENABLE trial. Key findings include a 44% cumulative MMR rate (16 of 36 patients) by 24 weeks, with favorable safety and tolerability profiles. The company maintains a strong financial position with $289.6 million in cash and equivalents, providing runway into late 2027. Q1 2025 resulted in a net loss of $28.5 million. Notably, Enliven plans to deprioritize its ELVN-002 program to focus on advancing ELVN-001 towards a potential pivotal trial in 2026. Updated ELVN-001 trial data will be presented at the EHA 2025 Congress in June.

Enliven Therapeutics (NASDAQ: ELVN) reported updated positive data from its Phase 1 ENABLE clinical trial of ELVN-001 in chronic myeloid leukemia (CML) patients. Key highlights include:

The trial showed a 44% cumulative major molecular response (MMR) rate (16 of 36 patients) by 24 weeks, with 26% achieving and 100% maintaining MMR. The study enrolled 74 heavily pretreated patients, with 66% having received three or more prior tyrosine kinase inhibitors (TKIs).

ELVN-001, a selective BCR::ABL1 kinase inhibitor, demonstrated strong efficacy in resistant cases, with 40% of TKI-resistant patients achieving MMR. The drug showed a favorable safety profile across all doses, with low rates of dose interruptions (<10%) and reductions (<5%). The results will be presented at the EHA 2025 Congress in Milan.

Enliven Therapeutics (Nasdaq: ELVN) has announced it will present five posters at the 2025 AACR Annual Meeting in Chicago from April 25-30, 2025. The presentations will showcase their pipeline of small molecule therapeutics, including:

- ELVN-002: A selective HER2 inhibitor with potential enhanced efficacy in combination with antibody-drug conjugates
- ELVN-001: A selective ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia treatment
- ELV-3111: A type 1 pan-RAF inhibitor for NRAS and BRAF mutant cancers

The presentations will cover pharmacokinetics, drug resistance mechanisms, and combination therapy approaches. All posters will be presented on April 29, 2025, across different sessions and locations at the conference.

Enliven Therapeutics (ELVN) has reported its Q4 and full year 2024 financial results, highlighting continued progress in its clinical programs. The company maintains a strong financial position with $313.4 million in cash and equivalents, providing runway into mid-2027.

Key pipeline updates include anticipated Phase 1 data for ELVN-001, their BCR::ABL kinase inhibitor for chronic myeloid leukemia (CML), expected mid-2025. Their second program, ELVN-002, a CNS-penetrant HER2 inhibitor, will report both monotherapy and combination trial data in H2 2025.

Financial highlights for FY2024 show R&D expenses of $80.8 million (up from $64.6M in 2023), G&A expenses of $23.8 million (up from $19.0M), and a net loss of $89.0 million (compared to $71.6M in 2023). The company is preparing for a potential pivotal trial of ELVN-001 in 2026.

Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage biopharmaceutical company specializing in small molecule therapeutics discovery and development, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will engage in a fireside chat scheduled for Tuesday, March 4, 2025, at 10:30 a.m. ET.

The event will be accessible through a live webcast on the company's investor relations website at ir.enliventherapeutics.com. Interested parties who cannot attend the live session can access the archived recording, which will remain available for 90 days after the event's conclusion.

Enliven Therapeutics (ELVN) reported positive Phase 1 trial results for ELVN-001 in CML patients, achieving a 44.4% (8/18) cumulative major molecular response rate by 24 weeks. The drug remained well-tolerated with no dose reductions. The company continues advancing ELVN-002 trials in HER2+ metastatic breast cancer and colorectal cancer. Financial results show $291.8 million in cash and equivalents, providing runway into late 2026. Q3 2024 resulted in a net loss of $23.2 million, with R&D expenses at $21.3 million and G&A expenses at $5.8 million.